Page 1453 - Williams Hematology ( PDFDrive )

1428 Part X: Malignant Myeloid Diseases Chapter 88: Acute Myelogenous Leukemia 1429

788. Faderl S, Ferrajoli A, Wierda W, et al: Clofarabine combinations as acute myeloid leu- 819. van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al: Targeting of the CD33-
kemia salvage therapy. Cancer 113:2090, 2008. calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In
789. Faderl S, Wetzler M, Roizzieri D, et al: Clofarabine plus cytarabine compared with vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.
cytarabine alone in older patients with relapsed or refractory acute myelogenous leu- Blood 97:3197, 2001.
kemia: Results from the CLASSIC 1 Trial. J Clin Oncol 30:2492, 2012. 820. Lang K, Menzin J, Earle CC, Mallick R: Outcomes in patients treated with gemtu-
790. Greinix HT, Keil F, Brugger SA, et al: Long-term leukemia-free survival after allo- zumab ozogamicin for relapsed acute myelogenous leukemia. Am J Health Syst Pharm
geneic marrow transplantation in patients with acute myelogenous leukemia. Ann 59:941, 2002.
Hematol 72:53, 1996. 821. Leopold LH, Berger MS, Cheng SC, et al: Comparative efficacy and safety of Gemtu-
791. Appelbaum FR: Hematopoietic cell transplantation beyond first remission. Leukemia zumab ozogamicin monotherapy and high-dose cytarabine combination therapy in
16:157, 2002. patients with acute myeloid leukemia in first relapse. Clin Adv Hematol Oncol 1:220,
792. Singhal S, Powles R, Henslee-Downey PJ, et al: Allogeneic transplantation from HLA- 2003.
matched sibling or partially HLA-missmatched related donors for primary refractory 822. Wadleigh M, Richardson PG, Zahrieh D, et al: Prior gemtuzumab ozogamicin expo-
acute leukemia. Bone Marrow Transplant 29:291, 2002. sure significantly increases the risk of veno-occlusive disease in patients who undergo
793. Biggs JC, Horowitz MM, Gale RP, et al: Bone marrow transplants may cure patients myeloablative allogeneic stem cell transplantation. Blood 102:1578, 2003.
with acute leukemia never achieving remission with chemotherapy. Blood 80:1090, 823. Stasi R, Evangelista ML, Buccisano F, et al: Gemtuzumab ozogamicin in the treatment
1992. of acute myeloid leukemia. Cancer Treat Rev 34:49, 2008.
794. Arellano ML, Langston A, Winton E, et al: Treatment of relapsed acute leukemia after 824. Burnett AK, Russell NH, Hills RK, et al: Addition of gemtuzumab ozogamicin in
allogeneic transplantation: A single center experience. Biol Blood Marrow Transplant induction chemotherapy improves survival in older patients with acute myeloid leu-
13:116, 2007. kemia. J Clin Oncol 30:3924, 2012.
795. Pollyea DA, Artz AS, Stock W, et al: Outcomes of patients with AML and MDS who 825. Castaigne S, Pautas C, Terré C, et al: Effect of gemtuzumab ozogamicin on survival of
relapse or progress after reduced intensity allogeneic hematopoietic cell transplanta- adult patients with de-novo acute myeloid leukaemia (ALFA-07010). A randomized,
tion. Bone Marrow Transplant 40:1027, 2007. open-label, phase 3 study. Lancet 379:1508, 2012.
796. Lancet JE, Cortes JE, Hogge DE, et al: Phase 2 trial of CPX-351, a fixed 5:1 molar 826. Weisberg E, Boulton C, Kelly LM, et al: Inhibition of mutant FLT3 receptors in leuke-
ration of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with mia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1:433,
untreated AML. Blood 123:3238, 2014. 2002.
797. Rush LJ, Dai Z, Smiraglia DJ, et al: Novel methylation targets in de novo acute myeloid 827. Kelly LM, Yu JC, Boulton CL, et al: CT53518, a novel selective FLT3 antagonist for the
leukemia with prevalence of chromosome 11 loci. Blood 97:3226, 2001. treatment of acute myelogenous leukemia (AML). Cancer Cell 1:421, 2002.
798. Blum W, Marcucci G: Targeting epigenetic changes in acute myeloid leukemia. Clin 828. Levis M, Allebach J, Tse KF, et al: A FLT3-targeted tyrosine kinase inhibitor is cyto-
Adv Hematol Oncol 3:855, 2005. toxic to leukemia cells in vitro and in vivo. Blood 99:3885, 2002.
799. Lübbert M, Minden M: Decitabine in acute myeloid leukemia. Semin Hematol 829. Spiekermann K, Dirschinger RJ, Schwab R, et al: The protein tyrosine kinase inhibitor
42(Suppl 2):S38, 2005. SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell
800. Kihslinger JE, Godley LA: The use of hypomethylating agents in the treatment of lines expressing a constitutively activated FLT3. Blood 101:1494, 2003.
hematologic malignancies. Leuk Lymphoma 48:1676, 2007. 830. DeAngelo DJ, Stone RM, Heaney ML, et al: Phase 1 clinical results with tandutinib
801. Plimack ER, Kantarjian HM, Issa JP, et al: Decitabine and its role in the treatment of (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia
hematopoietic malignancies. Leuk Lymphoma 48:1472, 2007. or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacody-
802. Garcia-Manero G, Stoltz ML, Ward MR, et al: A pilot pharmacokinetic study of oral namics. Blood 108:3674, 2006.
azacitidine. Leukemia 22:1680, 2008. 831. Tickenbrock L, Müller-Tidow C, Berdel WE, Serve H: Emerging Flt3 kinase inhibitors
803. Kantarjian HM, O’Brien SM, Estey E, et al: Decitabine studies in chronic and acute in the treatment of leukaemia. Expert Opin Emerg Drugs 11:153, 2006.
myelogenous leukemia. Leukemia 11(Suppl 1):S35, 1997. 832. Fathi AT, Le L, Hasserjian RP: FLT3 inhibitor-induced neutrophilic dermatosis. Blood
804. Yan P, Frankhouser D, Murphy M, et al: Genome-wide methylation profiling in decit- 122:239, 2013.
abine-treated patients with acute myeloid leukemia. Blood 120:2466, 2012. 833. Pratz KW, Sato T, Murphy KM, et al: FLT3-mutant allelic burden and clinical status
805. Blum W, Garzon R, Kilisovic RB, et al: Clinical response and miR-29B predictive sig- are predictive of response to FLT3 inhibitors in AML. Blood 115:1425, 2010.
nificance in older patients treated with a 10-day schedule of decitabine. Proc Natl Acad 834. Stone RM, De Angelo DJ, Klimek V, et al: Patients with acute myeloid leukemia and
Sci U S A 107:7473, 2010. an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase
806. Ferrara EF, Fazi F, Bianchini A, et al: Histone deacetylase-targeted treatment restores inhibitor. Blood 105:54, 2005.
retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61:2, 835. Knapper S, Burnett AK, Littlewood T, et al: A phase 2 trial of the FLT3 inhibitor les-
2001. taurtinib (CEP701) as first-line treatment for older patients with acute myeloid leuke-
807. Klisovic MI, Maghraby EA, Parthun MR, et al: Depsipeptide (FR 901228) promotes mia not considered fit for intensive chemotherapy. Blood 108:3262, 2006.
histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA 836. Kindler T, Lipka DB, Fischer T: FLT3 as a therapeutic target in AML: Still challenging
methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17:350, after all these years. Blood 116:5089, 2010.
2003. 837. Zimmerman EI, Turner DC, Buaboonnam J, et al: Crenolanib is active against models
808. Klimek VM, Fircanis S, Maslak P, et al: Tolerability, pharmacodynamics, and phar- of drug-resistant FLT3-ITD—positive acute myeloid leukemia. Blood 122:3607, 2013.
macokinetics studies of depsipeptide (romidepsin) in patients with acute myeloge- 838. Cortes JE, Kantarjian H, Foran JM, et al: Phase I study of quizartinib administered
nous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 14:826, daily to patients with relapsed or refractory acute myeloid leukemia irrespective of
2008. FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol 31:3681,
809. Giles F, Fischer T, Cortes J, et al: A phase I study of intravenous LBH589, a novel 2013.
cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with 839. Fischer T, Stone RM, DeAngelo DJ, et al: Phase IIB trial of oral midostaurin (PKC412),
refractory hematologic malignancies. Clin Cancer Res 12:4628, 2006. the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in
810. Garcia-Manero G, Yang H, Bueso-Ramos C, et al: Phase 1 study of the histone deacet- patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with
ylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with either wild-type of mutated FLT3. J Clin Oncol 28:4339, 2010.
advanced leukemias and myelodysplastic syndromes. Blood 111:1060, 2008. 840. Ravandi F, Cortes JE, Jones D, et al: Phase I/II study of combination therapy with
811. Garcia-Manero G, Assouline S, Cortes J, et al: Phase 1 study of the oral isotype specific sorafenib, idarubicin, and decitabine in younger patients with acute myeloid leuke-
histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112:981, 2008. mia. J Clin Oncol 28:1856, 2010.
812. Gore SD: Combination therapy with DNA methyltransferase inhibitors in hemato- 841. Heinrich MC, Blanke CD, Druker BJ, Corless CL: Inhibition of KIT tyrosine kinase
logic malignancies. Nat Clin Pract Oncol 2 Suppl 1:S30, 2005. activity: A novel molecular approach to the treatment of KIT-positive malignancies. J
813. Blum W, Klisovic RB, Hackanson B, et al: Phase I study of decitabine alone or in com- Clin Oncol 20:1692, 2002.
bination with valproic acid in acute myeloid leukemia. J Clin Oncol 25:3884, 2007. 842. Kindler T, Breitenbuecher F, Marx A, et al: Sustained complete hematologic remission
814. Daigle SR, Oihava EJ, Therkeisen CA, et al: Potent inhibition of DOT1L as treatment after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient
of MLL-fusion leukemia. Blood 122:1017, 2013. with refractory, secondary AML. Blood 101:2960, 2003.
815. Sarkaria SM, Christopher MJ, Klco JM, Ley TJ: Primary acute myeloid leukemia 843. Kindler T, Breitenbuecher F, Marx A, et al: Efficacy and safety of imatinib in adult
cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro. Leukemia patients with C-kit-positive acute myeloid leukemia. Blood 103:3644, 2004.
28:2403, 2014. 844. Marcucci G, Geyer S, Zhao J, et al: Adding the KIT inhibitor Dasatinib (DAS) to stan-
816. Lee WY, Chen KC, Chen HY, Chen CY: Potential mitochondrial isocitrate dehydro- dard induction and consolidation therapy for newly diagnosed patients (pts) with core
genase R140Q mutant inhibitor from traditional Chinese medicine against cancers. binding factor (CBF) acute myeloid leukemia (AML): Initial results of the CALGB
Biomed Res Int 2014:364625, 2014. 10801 (Alliance) study [abstract]. Blood 122:2013.
817. Lu M, Xia L, Li Y, et al: The orally bioavailable MDM2 antagonist RG7112 and pegy- 845. Guzman ML, Jordan CT: Considerations for targeting malignant stem cells in leuke-
lated interferon α 2a target JAK2V617F-positive progenitor and stem cells. Blood mia. Cancer Control 11:97, 2004.
124:771, 2014. 846. Cilloni D, Messa F, Rosso V, et al: Increase sensitivity to chemotherapeutical agents
818. Larson RA: Current use and future development of gemtuzumab ozogamicin. Semin and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in
Hematol 38:24, 2001. AML carrying NPM1 mutations. Leukemia 22:1234, 2008.

Kaushansky_chapter 88_p1373-1436.indd 1428 9/21/15 11:02 AM